Improving Healthcare Delivery in Immuno-Oncology: A Global Quality Improvement Initiative-Module 1

Curriculum:
A Global Quality Improvement Initiative in Immuno-Oncology
Credits:
1.5 AMA PRA Category 1 Credits
Launch Date:
26-Apr-18
Expiration Date:
26-Apr-19

Primary Audience:

Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses, And Other Healthcare Providers

Relevant Terms:

Immunotherapy, Quality Improvement

Joseph Jacobson, MD

Joseph Jacobson, MD
Chief Quality Officer
Dana Farber Cancer Institute
Boston, Massachusetts, United State

Joseph Jacobson, MD, serves as chief quality officer at the Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts, United States, where he is responsible for patient safety and quality of care in the principal disciplines of oncology at the main institution and its network programs. He is trained in medical oncology and hematology, holds a master’s degree in epidemiology, and completed advanced training at the Intermountain Healthcare Institute for Healthcare Delivery Research in Utah, United States. He has practiced extensively in both academic and community settings. He is an associate professor of medicine at Harvard Medical School in Massachusetts.
 
Joe is committed to creating innovations in quality of care and patient safety. As chief quality officer at the DFCI, he is engaged in multiple projects locally, regionally, and nationally to define and improve care delivery by applying the tools of quality improvement. For over five years, he has co-led a five-month, project-based training program at Partners Healthcare in Massachusetts that has trained hundreds of clinicians in how to undertake quality improvement. He currently mentors physicians and other clinicians in quality improvement and patient safety, develops systems to measure, standardize and improve care, and continues to create the needed capacity for broad training in quality improvement leadership locally and nationally. 

Timothy Gilligan, MD

Timothy Gilligan, MD
Vice-Chair for Education
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, United States

Timothy Gilligan, MD, is a medical oncologist, vice-chair for Education, and associate professor of medicine at the Cleveland Clinic Taussig Cancer Institute in Ohio, United States. He specializes in cancers of the testicles, kidneys, prostate, and bladder. Dr Gilligan is director of coaching at the Cleveland Clinic Center for Excellence in Healthcare Communication, and co-editor of the book Communication the Cleveland Clinic WayAt Cleveland Clinic and other hospitals and at national and international conferences, he teaches communication skills, team-building, and coaching, and trains others to teach communication skills. Dr Gilligan works on quality of care and clinical practice guidelines with the American Society of Clinical Oncology (ASCO) and the National Cancer Institute, and chairs the testis cancer panel for the National Comprehensive Cancer Network (NCCN). He helps teach the ASCO Quality Training Program and co-chairs the ASCO Panel writing guidelines on patient-physician communication. He speaks regularly at national oncology meetings and board review courses and urologic cancers and healthcare communication.
 
Dr Gilligan graduated from Stanford University School of Medicine in California and Columbia University Graduate School of Journalism in New York in the United States. He trained in internal medicine and medical oncology at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute in Massachusetts, United States. He completed the American Academy on Communication in Healthcare three-year faculty training program and is a member of their faculty. He also completed the OncoTalk Teach program.

John B Haanen, MD, PhD

John B Haanen, MD, PhD
Molecular Oncology & Immunology Group Leader
Netherlands Cancer institute
Amsterdam, the Netherlands

John B. Haanen, MD, PhD, is head of the Division of Medical Oncology and staff scientist in the Division of Immunology at the Netherlands Cancer Institute in Amsterdam. He is also professor of translational immunotherapy of cancer at Leiden University Medical Centre, the Netherlands.
 
Dr Haanen received his medical degree from the University of Leiden, then completed a PhD on human CD4+ helper T cells at the Department of Immunohematology and the Blood Bank of the Leiden University Medical Centre and the DNAX Research Institute in California, United States.
 
He then trained in internal medicine at Leiden University Medical Centre and at Bronovo Hospital in The Hague, the Netherlands. He did a postdoctoral fellowship in tumor immunology at the division of immunology, followed by training in medical oncology at the Netherlands Cancer Institute.
 
His research focuses on the translation of novel immunotherapy strategies into the clinical practice, especially adoptive cell transfer programs and immune checkpoint blockade. His clinical medical oncology practice is focused on patients with melanoma and renal cell carcinoma.
 
Dr Haanen is a co-founder of the Amsterdam Biotherapeutics Unit and was chairman of The Dutch Tumor Immunology Working Party for Oncology for many years. He is currently a European Society for Medical Oncology (ESMO) faculty chair for immunotherapy of cancer.
 
He serves on various national and international advisory boards and committees, including the editorial board of Current Oncology Reports and ESMO Open.
 
1. Develop optimum treatment strategies using checkpoint inhibitors to treat a variety of tumor types
2. Create approaches to monitor and manage immune-related adverse events (irAEs) resulting from treatment with immune checkpoint inhibitors
3. Discuss best practices related to shared decision making in clinical practice
4. Describe foundational principles of quality improvement as they relate to healthcare

PROVIDER
This activity is provided by prIME Oncology.
CONTINUING MEDICAL EDUCATION
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



prIME Oncology designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
SUNSHINE ACT/EFPIA
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements. 
 
SUPPORT
This activity is supported by educational grants from Bristol-Myers Squibb, EMD Serono, and Pfizer.
 
DISCLOSURES
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity.
 
Dr Gilligan has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Haanen has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Jacobson has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
 
The employees of prIME Oncology have disclosed:
  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
 
DISCLOSURE REGARDING UNLABELED USE
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.